Clinical Trials Logo

Clinical Trial Summary

This is a single-patient access (also referred to as Compassionate Use) setting for a patient who has been treated and benefited from RO7070179 while participating in a clinical study of RO7070179. The patient will receive the dose of RO7070179 at 6 mg/kg/week by IV infusion. Treatment cycles will be defined as 42 (6 weeks) days.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03496051
Study type Expanded Access
Source New York University School of Medicine
Contact Jennifer Wu, MD
Phone 212-263-6485
Status Available

See also
  Status Clinical Trial Phase
Recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Recruiting NCT03655613 - CBT-501 or Nivolumab in Combination With CBT-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT03222076 - Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956) Phase 2
Recruiting NCT03219372 - Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence Phase 2
Active, not recruiting NCT01908426 - Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Phase 3
Active, not recruiting NCT01658878 - An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Phase 1/Phase 2
Not yet recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Not yet recruiting NCT03172559 - Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI) N/A
Recruiting NCT02854839 - A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma Phase 2
Recruiting NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT02743065 - HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China
Recruiting NCT02809534 - A Study of Anlotinib in Patients With Hepatocellular Carcinoma Phase 2
Recruiting NCT02643173 - Hepatocellular Carcinoma Recurrence and Anesthesia N/A
Active, not recruiting NCT02525380 - Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma Phase 4
Active, not recruiting NCT02534337 - Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Active, not recruiting NCT02527772 - Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma Phase 2/Phase 3
Terminated NCT02549755 - 11C-acetate for Treatment Response After Radiotherapy for HCC Phase 2
Recruiting NCT02174549 - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer Phase 1/Phase 2
Recruiting NCT02128958 - Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) Phase 2